EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Measurement of PDE5 concentration in human serum: proof-of-concept and validation of methodology in control and prostate cancer patients

Giovanni Luca Gravina, Eugenia Guida, Maria Dri, Renato Massoud, Savino M Di Stasi, Giorgio Fucci, Andrea Sansone, Susanna Dolci, Emmanuele A Jannini

Journal of Endocrinological Investigation · 2024

DOI: 10.1007/s40618-024-02428-w ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Endocrinological Investigation, 2024. Verfasst von Giovanni Luca Gravina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 5, Prostatic Neoplasms, Biomarkers, Tumor, Prostatic Hyperplasia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma Tor Vergata.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We aimed to investigate if the type 5 phosphodiesterase (PDE5), an enzyme with cardinal biological functions in sexual and cardiovascular health, can be detected and quantited in human serum.

Methods

Blood samples were collected from control male and female subjects. PDE5 levels were measured by a specific ELISA kit. ROC curves weighted for age and serum levels of PSA (male subjects), or age (female subjects) were used to identify the predictive ability in the detection of PCa. Sensitivity, specificity, PPV and NPV values were determined for cut-off value determined during ROC curve analysis.

Results

41 control male subjects, 18 control female subjects, and 55 consecutive subjects, of which 25 were affected by benign prostatic hypertrophy (BPH) and 30 with histologically confirmed prostate cancer (PCa), were studied. PDE5 serum levels were detectable in all subjects (range: 5 to 65 ng/ml). Analysis by MANCOVA identified a significant difference in serum PDE5 between control subjects or hyperplasia patients and PCa patients. Marginal means of serum PDE5 concentrations showed a significant difference ( p < 0.001). The ROC curve demonstrated that PDE5 serum levels can predict men with or without PCa, with 0.806 AUC value ( p < 0.0001). Using a 12.705 ng/ml PDE5 serum cut-off yielded sensitivity, specificity, PPV, and NPV of 83.3%, 77.27%, 62.5%, and 91.1% in detecting men with histologically proven PCa, respectively.

Conclusions

We demonstrated, for the first time, that PDE5 levels can be detected in human sera and that PCa patients have significantly higher PDE5 concentration compared to BPH patients or male and female controls. While serum PDE5 level measurement may open new research avenues, the clinical relevance of PDE5 levels in PCa patients deserves further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclic Nucleotide Phosphodiesterases, Type 5Prostatic NeoplasmsBiomarkers, TumorProstatic HyperplasiaHumansMaleFemaleAgedMiddle AgedROC CurveCase-Control StudiesProof of Concept StudyEnzyme-Linked Immunosorbent AssayAged, 80 and overProstate-Specific Antigen

Stichwörter der Autor:innen

Benign prostatic hyperplasiaNovel markers of diseasePhosphodiesterase type 5Prostate cancer

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 5Biomarkers, TumorPDE5A protein, humanProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy.
  • Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Chair of Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Tower E south, Room E 413, Via Montpellier 1, Rome, 00133, Italy.
  • Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy. eajannini@gmail.com.
  • Chair of Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Tower E south, Room E 413, Via Montpellier 1, Rome, 00133, Italy. eajannini@gmail.com.

Förderung

  • Università degli Studi di Roma Tor Vergata

Zitieren

APA

Gravina, G. L., Guida, E., Dri, M., Massoud, R., Di Stasi, S. M., Fucci, G., Sansone, A., Dolci, S., & Jannini, E. A. (2024). Measurement of PDE5 concentration in human serum: proof-of-concept and validation of methodology in control and prostate cancer patients. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02428-w

Vancouver

Gravina GL, Guida E, Dri M, Massoud R, Di Stasi SM, Fucci G, et al. Measurement of PDE5 concentration in human serum: proof-of-concept and validation of methodology in control and prostate cancer patients. Journal of Endocrinological Investigation. 2024. doi:10.1007/s40618-024-02428-w

BibTeX
@article{Gravina2024,
  author = {Gravina, Giovanni Luca and Guida, Eugenia and Dri, Maria and Massoud, Renato and Di Stasi, Savino M and Fucci, Giorgio and Sansone, Andrea and Dolci, Susanna and Jannini, Emmanuele A},
  title = {Measurement of PDE5 concentration in human serum: proof-of-concept and validation of methodology in control and prostate cancer patients},
  journal = {Journal of Endocrinological Investigation},
  year = {2024},
  doi = {10.1007/s40618-024-02428-w}
}
Kostenlos starten →